KCT0007602招募中未知
Phase II study of Concurrent Tislelizumab and Radiotherapy for treatment-naïve, newly diagnosed low-risk extranodal NK/T-cell lymphoma, nasal type
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 38
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1. Histologicallly diagnosed extranodal NK/T-cell lymphoma
- •2. No history of prior treatment
- •3. Stage IE/IIE(cases involving the nasal cavity, nasopharynx, and oral cavity only)
- •4. International prognostic index(PINK, PINK-E risk score): 0-1
- •5. 19 years and older
- •6. ECOG PS: 0-2
- •7. AT least one measurable and assessable lesion at least 1.5cm in size on CT or PET/CT scan
- •8. Adequate bone marrow function, as defined by the following laboratory values(If cytopenia is associated with bone marrow involvement, the subject is excluded):
- •- Absolute neutrophil > 1,500/mm3
- •- Hemoglobin > 9.0g/dL
- •- Platelet > 75,000/mm3
- •9. Adequate organ function, as defined by the following laboratory values
- •- Total bilirubin, AST/ALT < 3xULN
- •- Serum creatinine = 2.0mg/dL
- •10. Voluntary written informed consent to undergo chemotherapy and radiotherapy
- •11. Female subjects are required to meet the following criteria:
- •- Pregnancy test: For women of childbearing potential, a negative serum or urine pregnancy test at screening
- •- Contraception: For both male and female subjects, use of highly effective contraception throughout the study period and, if at risk of pregnancy, for at least 6 months after the last dose of the study treatment
- •12. Having tumor tissue sample in storage available for targeted sequencing
排除标准
- •1. History of prior treatment(chemotherapy, radiotherapy, or targeted therapy) to treat extranodal NK/T-cell lymphoma
- •2. Stage III/IV at diagnosis or stage IE-IIE with extranodal(cutaneous, soft tissue, gastrointestinal, brain, spinal cord, bone marrow, etc.)
- •3. International prognostic index(PINK, PINK-E): = 2
- •4. Has a concomitant malignancy or had a malignancy(except for appropriately treated basal or squamous cell carcinoma or cervical carcinoma in situ) in the last 3 years prior to initiation of the study treatment
- •5. Underwent a major surgery within 21 days prior to initiating the study treatment, or has not recovered from serious side effects of surgery
- •6. Concomitant use of immunosuppressants, except for the following:
- •- Intranasal, inhaled, or topical steroid, or local steroid injection(such as intra-articular injection)
- •- Physiological dose = 10mg/day of prednisone or equivalent doses of systemic corticosteroid
- •- Premedication with steroids to prevent hypersensitivity reaction(such as premedication prior to a CT scan). At the discretion of the investigator, the use of prednisolone at = 10mg for adrenal insufficiency may be acceptable
- •7. Clinically significant, or active, cardiovascular disease
- •- Cerebrovascular accient/stroke: within 6 months prior to study entry
- •- Myocardial infarction: within 6 months prior to study entry
- •- Unstable angina, congestive heart failure(New York Heart Association class =II), or serious cardiac arrhythmias requiring medication, including any of the following
- •? Left ventricular ejection fraction(LVEF) < 50% as measured by echocardiography
- •? QTc>480msec(using the QTcF formula) on ECG at screening
- •? unstable angina
- •? ventricular arrhythmias except for benign premature ventricular contractions
- •? medically uncontrolled supraventricular and nodal arrhythmias
- •? conduction abnormality requiring a pacemaker
- •? valve disease with documented cardiac dysfunction
- •8. Other concomitant severe and/or uncontrolled medical conditions(e.g., uncontrolled diabetes mellitus, chronic pancreatitis, active chronic hepatitis, etc.) that the investigator considers would preclude the subjects's participation in the clinical trial. Other severe acute or chronic medical conditions include colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis, or psychiatric conditions, including recent(in the last 1 year) or active suicidal thoughts or behaviors: or laboratory abnormalities the, in the investigator's opinion, may increase the risk associated with participation in the clinical trial or study treatment, or that may interfere with the interpretation of clinical trial results.
- •9. Active infection requiring ststemic therapy
- •10. Active autoimmune disease that may be exacerbated upon administration of immunostimulants. However, subjects with type I diabetes mellitus, vitiligo, psoriasis, or hypothyroidism or hyperthyroidism not requiring immunosuppressive treatment are eligible
- •11. Incapable of understanding or complying with clinical trial instructions and requirements, or have a history of noncompliance with medical therapy
- •12. Pregnant or nursing(breastfeeding) women. Pregnancy is defined as the condition of a woman form pregnancy as confirmed by positive serum hCG laboratory test(>5mIU/mL) to termination of pregnancy.
- •13. Live vaccination is prohibited, except for influenza and COVID vaccines are allowed, within 2 weeks prior to the first dose
研究者
相似试验
进行中（未招募）
1 期
Phase II study of Atezolizumab plus Tiragolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal.Squamous cell carcinoma of the anal canalMedDRA version: 26.0Level: LLTClassification code: 10084945Term: Basaloid squamous cell carcinoma of the anal canal Class: 100000004848CTIS2023-509485-38-00Grupo Espanol Multidisciplinar En Cancer Digestivo45
招募中
2 期
Tislelizumab in Combination With Chemotherapy in First-line Treatment of Unresectable/Metastatic Non-small Cell Lung Cancer or Recurrent/Metastatic Squamous Cell Head and Neck CancerCTRI/2024/03/063500B HEALTH TECHNOLOGIES PRIVATE LIMITED
进行中（未招募）
不适用
Phase II study of tislelizumab plus pemetrexed in patients with relapsed or refractory primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system (CNS)NeoplasmsKCT0007048Seoul National University Hospital28
进行中（未招募）
1 期
A Phase 1/2 Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid TumorsSolid tumorsMedDRA version: 19.1 Level: LLT Classification code 10066438 Term: Anorectal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10060121 Term: Squamous cell carcinoma of head and neck System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10030151 Term: Oesophageal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10005003 Term: Bladder cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.1 Level: LLT Classification code 10064444 Term: Invasive cervix cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10027481 Term: Metastatic melanoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and pEUCTR2016-001359-36-ESBristol-Myers Squibb International Corporation815
已完成
2 期
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell CarcinomaHead and Neck Squamous Cell CarcinomaHead and Neck CancerHead and Neck CancerNCT05909904BeiGene160